Gidazepam pellets – 3mg
€ 15,00 – € 175,00Price range: € 15,00 through € 175,00
Gidazepam Pellets 3mg are described as compressed research pellets containing a nominal 3 mg of gidazepam per unit.
Gidazepam is a benzodiazepine-related compound historically investigated in clinical and pharmacological settings. It is associated with central nervous system depressant activity and active metabolites.
The supplied specifications report CAS number 129186-29-4, molecular formula C16H13BrClN4, and molecular weight 377.66 g/mol.
The reported formula and molecular weight require reconciliation. The supplied systematic name also requires confirmation against the actual gidazepam structure.
The source claims ingredient purity of at least 98%, independent analytical testing, batch traceability, and consistent pellet weight.
No batch-specific Certificate of Analysis, finished-pellet assay, or content-uniformity dataset was supplied.
The nominal 3 mg label claim should not be treated as an independently verified quantitative measurement.
Benzodiazepine-related hazards include sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Gidazepam Pellets 3mg – Research Material Information
Gidazepam Pellets 3mg – Product Overview
Gidazepam Pellets 3mg is the supplied catalog designation for compressed research pellets described as containing gidazepam.
The source specifies a nominal ingredient content of 3 mg per pellet.
This figure represents a label claim, not a verified finished-pellet assay.
The source positions the material within laboratory contexts involving benzodiazepine-related chemical identity, analytical documentation, and structural characterization.
No actual batch-specific Certificate of Analysis, finished-pellet content report, or independent laboratory record was supplied.
The material is not established as a certified reference standard or approved pharmaceutical product.
Chemical Identity & Classification
Gidazepam is a benzodiazepine-related compound associated with central nervous system depressant pharmacology.
The source provides the following specifications:
- Reported chemical name: Gidazepam
- Supplied synonym: 7-Bromo-5-(2-chlorophenyl)-3H-1,4-benzodiazepine-2-hydrazone
- Reported CAS number: 129186-29-4
- Supplied molecular formula: C16H13BrClN4
- Supplied molecular weight: 377.66 g/mol
- Reported form: Compressed pellets
- Nominal ingredient content: 3 mg per pellet
- Intended designation: Research Use Only
The supplied formula calculates to approximately 376.66 g/mol rather than the reported 377.66 g/mol.
The reported systematic name and molecular composition also require confirmation against the intended chemical structure.
The actual chemical identity, form, and CAS assignment should be verified before definitive specifications are published.
Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the actual compound.
Chemical & Physical Characteristics
The source describes compressed pellets containing gidazepam.
No actual product inspection record, pellet dimensions, hardness measurements, or disintegration data were supplied.
The source does not identify the excipients or establish the physical state of the ingredient within the pellet matrix.
Solubility and stability are mentioned as analytical considerations.
However, no validated finished-product measurements were provided.
The pellet format alone does not establish consistent dissolution, quantitative recovery, or uniform ingredient distribution.
Purity & Analytical Verification
The source claims ingredient purity of at least 98% by HPLC.
It also refers to HPLC, mass spectrometry, and NMR spectroscopy for identity confirmation.
No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.
The purity claim therefore remains unverified.
Ingredient purity and finished-pellet content are distinct measurements.
A high-purity ingredient does not establish that each pellet contains exactly 3 mg of gidazepam.
The source describes laboratory analytical applications, but no validated quantitative reference value or certified reference-material documentation was supplied.
The pellets should not be described as certified analytical standards without appropriate supporting records.
Quality Control & Batch Integrity
The source claims third-party laboratory testing, batch traceability, controlled manufacturing, and pellet-weight variation within approximately ±2%.
These claims are not supported by supplied batch-specific documentation.
No pellet-weight dataset, finished-pellet assay, content-uniformity report, or independent laboratory record was provided.
Pellet weight and active-ingredient content are separate properties.
A consistent total pellet mass does not independently establish uniform gidazepam content.
The Research Use Only designation does not demonstrate certified quality or validated analytical performance.
Safety, Handling & Laboratory Precautions
Gidazepam is a benzodiazepine-related compound associated with central nervous system depression.
Potential hazards include sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.
Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.
The source does not provide a verified product-specific Safety Data Sheet.
Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.
The pellet presentation does not imply suitability for human or animal administration.
Packaging, Labeling & Storage
The source describes compressed pellets supplied in resealable packaging.
No actual container specification, packaging-validation record, or finished-product stability study was supplied.
The source recommends cool, dry storage and suggests a temperature range of approximately 2–8°C.
No validated stability data were provided to establish that range as a confirmed storage requirement.
The source does not establish a verified shelf life or long-term protection against environmental degradation.
Inventory records should distinguish nominal label claims from verified batch information.
Intended Research Use & Market Positioning
The source places gidazepam within laboratory contexts involving benzodiazepine-related chemical identity, analytical characterization, and structural comparison.
No certified reference-material status or validated quantitative performance has been demonstrated.
The supplied Raw Lab Chems catalog references include Flunitrazolam Blotters, Gidazepam Pellets 3mg, and Gidazepam Pellets 3mg – Alternate Catalog Entry.
These listings may describe different compounds, duplicate catalog entries, or different product records.
Their chemical identity, formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.
Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.
Ordering, Availability & Fulfillment
The source claims international shipping, tracking, customs documentation, and compliant transport.
No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.
The source also refers to IATA and DOT compliance.
No applicable dangerous-goods classification, transport assessment, or supporting compliance documentation was provided.
No claim is therefore made that worldwide shipment or customs clearance is universally available or legally authorized.
Gidazepam may be controlled or otherwise restricted under applicable national and international laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Gidazepam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.
Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.
No therapeutic approval, consumer-use authorization, or certified analytical status is implied.
| Quantity (pellets) |
25 ,50 ,100 ,250 ,500 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.